Grey has advised Evolan Pharma AB in connection with the purchase of the pharmaceutical product Hydrokortison Trimb and all intellectual property rights and assets relating thereto from Trimb Healthcare AB, a company owned by Karo Pharma.
The Swedish Competition Authority has approved Evolan as the buyer of Hydrokortison Trimb and the closing of the transaction is expected on 29 November 2019.
Evolan is a Swedish pharmaceutical company focused on product development, sales and marketing of pharmaceuticals.
Karo Pharma is a pharmaceutical company specialised in sales and marketing of prescription pharmaceuticals and over-the-counter products sold in pharmacies and retail. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.